Skip to content
Limited Research

Prostamax

Prostamax (Lys-Glu-Asp-Pro/KEDP) is a synthetic tetrapeptide bioregulator from the Khavinson peptide family that demonstrates prostate-specific tissue effects.

Also known as: Synthetic Tetrapeptide, Prostate Bioregulator

Typical Dose 0.5-1mg daily
Storage Refrigerate reconstituted; store lyophilized powder away from light
How Often Once daily

Overview

Prostamax (Lys-Glu-Asp-Pro/KEDP) is a synthetic tetrapeptide bioregulator from the Khavinson peptide family that demonstrates prostate-specific tissue effects. Preclinical research shows anti-inflammatory and tissue-protective properties in chronic prostatitis models, with emerging interest in epigenetic chromatin regulation and anti-aging applications. Human clinical trial data remains limited.

Key Benefits

  • Chronic Prostatitis Management
  • Tissue Regeneration
  • Superior to Conventional Agents

Direct systemic delivery, optimal bioavailability for prostate tissue targeting, established preclinical protocols

Mechanism of Action

Subcutaneous injection provides systemic circulation for tissue-specific bioregulation of prostate gland cells

Research Protocols Injectable

GoalDoseFrequencyRoute
Prostate Health Support0.5-1mg dailyOnce dailySubcutaneous
Anti-Aging Protocol0.75mg dailyOnce daily for 10-20 daysSubcutaneous
Preclinical Reference (Rat Model)20 μg/kgDaily for 15 daysSubcutaneous

Research protocols from published literature — not dosing recommendations.

Peptide Interactions

  • Epitalon — Compatible: Both are Khavinson bioregulators with complementary mechanisms. Prostamax targets prostate tissue while Epitalon focuses on telomerase activation. Russian protocols combine multiple bioregulators for comprehensive anti-aging support.
  • Thymalin — Compatible: Safe combination supporting prostate-immune axis. Both are short Khavinson peptides with different tissue specificities. Long-term Russian studies show safety of multi-peptide bioregulator protocols.
  • Pinealon — Compatible: Different target tissues with no known interactions. Pinealon targets neurological pathways while Prostamax focuses on prostate tissue. Can be used in comprehensive bioregulator protocols.
  • BPC-157 — Compatible: Different mechanisms with no documented interactions. BPC-157 focuses on tissue repair and GI protection while Prostamax provides prostate-specific bioregulation.
  • 5-Alpha Reductase Inhibitors — Use Caution: Both affect prostate tissue - effects may overlap or be amplified. Monitor for enhanced effects and consult healthcare provider if using together.
  • Testosterone/TRT — Monitor Combination: Both influence prostate tissue. Theoretical concern for combined effects on prostate growth. Monitor PSA levels and prostate symptoms if using together.
  • Saw Palmetto (Serenoa repens) — Compatible: Preclinical studies compared Prostamax favorably to Serenoa repens extract. Different mechanisms - may provide complementary prostate support.

Peptide Instructions Injectable

Supplies:

  • Lyophilized Prostamax powder (20mg vial)
  • Bacteriostatic water for injection (2mL)
  • Insulin syringes (30-31 gauge)
  • Alcohol swabs
  • Sterile vials for mixing

How to Reconstitute Injectable

  1. 1Remove lyophilized powder from refrigeration and allow to reach room temperature
  2. 2Clean vial tops with alcohol swabs and allow to dry completely
  3. 3Add 2.0mL bacteriostatic water to achieve 10mg/mL concentration
  4. 4Inject water slowly down the side of the vial to minimize foaming
  5. 5Gently swirl (do not shake) until powder dissolves completely - solution should be clear
  6. 6Store reconstituted solution in refrigerator at 2-8°C
  7. 7Use within 14 days of reconstitution for optimal potency

What to Expect Injectable

Week 1-2: Subtle improvements may begin; reduced inflammation markers in preclinical models. Week 2-3: Enhanced tissue function and cellular activity based on animal studies. Week 3-4: Peak effects observed in preclinical research protocols. Side effects: Mild injection site reactions possible. Note: Human clinical data is limited - effects extrapolated from preclinical research.

Side Effects & Safety

Human clinical trial data not yet published - dosing extrapolated from preclinical models. Possible mild injection site reactions (redness, swelling). Rare reports of mild digestive discomfort or headache. Contraindicated when active prostate malignancy exists - theoretical concern for tumor growth stimulation. Not recommended during pregnancy or lactation. Quality sourcing critical - verify purity and avoid contaminated products.

Human clinical trial data not yet published - dosing extrapolated from preclinical models. Possible mild injection site reactions (redness, swelling). Rare reports of mild digestive discomfort or headache. Contraindicated when active prostate malignancy exists - theoretical concern for tumor growth stimulation. Not recommended during pregnancy or lactation. Quality sourcing critical - verify purity and avoid contaminated products.

Community Insights

Prostamax should be stored at Refrigerate at 2-8°C, use within 14 days.

Molecular Information

Molecular Weight 487.5 Da
Length 4
Type Tetrapeptide
Sequence Lys-Glu-Asp-Pro (KEDP)

References

  1. Peptide bioregulators: the new class of geroprotectors Khavinson, V.K. · Advances in Gerontology 2022
  2. Benign Prostatic Hyperplasia Model · 2014
  3. Experimental studying of the drug efficiency Prostamax in the therapy of chronic aseptic prostatitis and its complications Borovskaya, T.G., Pakhomova, A.V., Goldberg, V.E., et al. · Modern Research in Inflammation 2013
  4. Chronic Aseptic Prostatitis - Rat Model · 2013
  5. Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro) Dzhokhadze, T.A., Buadze, T.Z., Gaĭozishvili, M.N., et al. · Georgian Medical News 2012
  6. Deheterochromatinization in Aging · 2012
  7. Effects of short peptides on lymphocyte chromatin in senile subjects Khavinson, V.K., Lezhava, T.A., Malinin, V.V. · Bulletin of Experimental Biology and Medicine 2004
  8. The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ Meskhi, T., Khachidze, D., Barbakadze, Sh., et al. · Biofizika 2004
  9. Lymphocyte Chromatin in Elderly Subjects · 2004
  10. Heterochromatin Effects - Biofizika Study · 2004

Research reference only. Not medical advice.